vimarsana.com
Home
Live Updates
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results : vimarsana.com
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results : vimarsana.com
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter
Delivered $49.3 million in net income for the full year 2023, including $4.7...
Related Keywords
Massachusetts ,
United States ,
Japan ,
Michigan ,
Canada ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Phoenix ,
Arizona ,
America ,
Dan Monahan ,
Joshua Cohen ,
Sami Barmada ,
Camillel Bedrosian ,
Justin Klee ,
Linda Arsenault ,
Nasdaq ,
Exchange Commission ,
University Of Michigan School Medicine ,
Linkedin ,
Sunovion Pharmaceuticals ,
Amylyx Pharmaceuticals Inc ,
Portfolio Strategy At Otsuka Pharmaceutical Companies ,
Amylyx Pharmaceuticals ,
Company Phase ,
Twitter ,
International Symposium ,
North America ,
Progressive Supranuclear Palsy ,
Recent Business Highlights ,
Global Phase ,
Chief Medical ,
Chief Human Resources Officer ,
General Manager ,
Chief Human Resources ,
Portfolio Strategy ,
Otsuka Pharmaceutical ,
Michigan School ,
Fourth Quarter ,
Year Ended December ,
Safety Information ,
Enterohepatic Circulation Disorders ,
Pancreatic Disorders ,
Patients Sensitive ,
High Sodium ,
Private Securities Litigation Reform Act ,
Amylyx United States Securities ,
Amylyx Annual Report ,
Markets ,